Medicamen Biotech (BOM:531146) Debt-to-Asset : 0.00 (As of Dec. 2023)

Medicamen Biotech Debt-to-Asset Chart

Medicamen Biotech Annual Data
	Trend	Mar14	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
Debt-to-Asset		Get a 7-Day Free Trial					0.09	0.06	0.10	0.11	0.09

Medicamen Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															-	0.09	-	0.10	-

Competitive Comparison of Medicamen Biotech's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicamen Biotech's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Medicamen Biotech's Debt-to-Asset falls into.

Medicamen Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Medicamen Biotech's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Medicamen Biotech's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicamen Biotech  (BOM:531146) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Medicamen Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Medicamen Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicamen Biotech (BOM:531146) Business Description